CWCong Wang

Cong Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cong Wang has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Chuan Wang

    Affiliated Hospital of Hebei University, Clinical Medical College, Hebei University, Baoding, China (J.S., Yiyi Zhang, C.W.).

    1 shared publication
  • Jiabing Han

    The Key Laboratory of New Drug Pharmacology and Toxicology Hebei Medical 11 University 050017 Shijiazhuang China

    1 shared publication
  • Jing Yang

    Zhejiang Key Laboratory of Medical Epigenetics, Department of Pathology and Pathophysiology, School of Basic Medical Sciences, Hangzhou Normal University, Hangzhou 311121, China

    1 shared publication
  • Ran Zhao

    The Key Laboratory of New Drug Pharmacology and Toxicology, Hebei Medical University, Shijiazhuang 050017, China

    1 shared publication
  • Simeng Lv

    The Key Laboratory of New Drug Pharmacology and Toxicology Hebei Medical 11 University 050017 Shijiazhuang China

    1 shared publication
  • Xuyan Li

    The Key Laboratory of New Drug Pharmacology and Toxicology Hebei Medical 11 University 050017 Shijiazhuang China

    1 shared publication

Latest Publications

  • Open Access

    Fibroblast growth factor 13 deficiency attenuates doxorubicin-induced cardiotoxicity by regulating Parkin-mediated myocardial injury

    by Jiabing Han, Xuyan Li, Yiming Dong, Yidan Wang, Simeng Lv, Yiyi Zhang, Ran Zhao, Yingke Yan, Yanxue Han, Yu Wang, et al.

    The clinical use of doxorubicin (DOX) as a chemotherapeutic agent is limited by its cardiotoxic effects. Fibroblast growth factor (FGF) isoform 13, a distinct type of FGF, has been increasingly recognized as an important regulator of cardiovascular disease. However, its role in doxorubicin-induced cardiotoxicity remains unknown. Therefore, the objective of this study is to investigate the role and mechanism of FGF13 in doxorubicin-induced cardiac injury. C57BL/6 mice are used to establish Dox-induced cardiotoxicity models. The results reveal that mouse weight, cardiomyocyte cross-sectional area, ejection fraction and fractional shortening are decreased in the DOX group. In contrast, Fgf13 deficiency mitigate doxorubicin-mediated cardiotoxicity, as indicated by increased mouse weight, cardiomyocyte cross-sectional area, ejection fraction and fractional shortening. Mechanistically, the protein expressions of bax and cleaved caspase 3 are elevated in the DOX-treated group, along with decreased JC-1 fluorescence intensity and bcl-2 expression, whereas Fgf13 knockout prevented these alterations. In addition, Parkin, but not p53, interact with FGF13 and is upregulated in response to Fgf13 deficiency in a mouse model of doxorubicin-induced cardiotoxicity. Overall, Fgf13 knockout attenuates doxorubicin-induced cardiomyocyte apoptosis and mitochondrial damage through the modulation of Parkin, indicating that FGF13 may serve as a promising therapeutic target for DOX-induced cardiotoxicity.